CANN GROUP LIMITED — Capital/Financing Update 2017

Dec 11, 2017

==> picture [585 x 60] intentionally omitted <==

ASX ANNOUNCEMENT

12 DECEMBER 2017

NOTICE GIVEN UNDER SECTION 708A(5)(e) OF CORPORATIONS ACT

Cann Group Limited ( Cann ) (ASX: CAN) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ) that:

• (a) Cann has today issued 23,480,000 fully paid ordinary shares under a placement to certain institutional, professional and sophisticated investors announced on 4 December 2017 without disclosure to investors under Part 6D.2 of the Corporations Act ; and

• (b) as at the date of this notice:

  • (1) Cann has complied with the provisions of Chapter 2M of the Corporations Act as they apply to Cann;

  • (2) Cann has complied with section 674 of the Corporations Act ; and

  • (3) there is no information that is “excluded information” within the meaning of sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act .

Signed for and on behalf of Cann Group Limited.

Richard Baker

Company Secretary

For further information please contact: Peter Crock Matthew Wright Cann Group Limited NWR Communications +61 (0) 3 9095 7088 +61 (0) 451 896 420 contact@canngrouplimited.com matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – Canada’s second largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 19.9% shareholding.

==> picture [595 x 78] intentionally omitted <==